

# Axcentua

*"Driven by innovation and guided by nature"*

Company presentation  
at  
Sweden Bio Investment day  
March 22, 2010

---


**Axcentua Pharmaceuticals AB**  
Alfred Nobels Allé 10  
141 52 Huddinge, Sweden

Tele + 46-8-524 88 620  
Fax + 46-8-524 86 234  
Mobile +46-70-653 6848

**Anders Berkenstam , CEO**  
www.axcentua.com  
[anders.berkenstam@axcentua.com](mailto:anders.berkenstam@axcentua.com)

# Mission

- Generate break-through drugs for difficult to treat tumors
- Pioneer novel drug development strategy
- Crystal re-engineering of natural compounds
- Reduce drug development time, cost and risk for failure



# Founders & Board of Directors



**Anders Berkenstam, CEO, PhD, Associate Professor ( Founder)**  
VP R&D; 15 years in Biotech & Pharmaceutical Industry



**Stefan Rehnmark, CSO, PhD, Associate Professor (Founder)**  
Head of Pharmacology; 10 years in Biotech



**Michael-Robin Witt, CTO, PhD (Founder)**  
Head of HTS; 10 years in Biotech & Pharmaceutical Industry



**Urban Paulsson - Chairman of the Board, Lawyer**  
Partner KLA Law firm; head of Life Science practice




**Göran Smedegård, PhD**  
SVP Business Development; 25 years in Biotech & Pharmaceutical Industry



**William Gunnarsson**  
Founder and former CEO of Orphan Europe

Complementary experience from early discovery to  
building a successful company

# Initial focus on oncology




- **Difficult to treat tumors – such as**
  - Pancreatic cancer; 37.680 cases & 34.290 deaths (91%)
- **High unmet medical need – exceptionally low survival**
  - Five year survival rate of only 3-5% and 4th leading cause of cancer deaths
- **Limited improvements in treatment outcome**
  - Overall survival prolonged only marginally
- **Emerging concept; multi-targeted compounds**
  - Rational design: Complex and technical challenges
  - Natural compounds: Track-record but poor drug-like properties & IP constrains

Crystal re-engineering strategy of natural compounds  
pioneered by Axcentua


# Crystal re-engineering strategy




**Name:** Carbon  
**Symbol:** C  
**Atomic Number:** 6  
**Atomic Mass:** 12.0107



**Name:** Diamond  
**Symbol:** C  
**Atomic Number:** 6  
**Atomic Mass:** 12.0107



**Name:** Curcumine = natural compound  
**Symbol:**  $C_{21}H_{20}O_6$   
**Atomic Mass:** 368




**Name:** Drug  
**Symbol:**  $C_{21}H_{20}O_6$   
**Atomic Mass:** 368

Different crystalline forms exhibit different properties

# Technology



Crystal re-engineering screen to identify new crystalline forms of natural compounds

1



Select well-characterized natural compounds

2



Crystal re-engineering screen  
Identify new solid forms

3




Novel pharmaceuticals  
with clear clinical  
benefits



Improve pharmaceutical properties  
Obtain patent protection


# Crystal re-engineering of lead natural compound

- I. Several new crystalline forms identified
- II. AXP107-11 selected as clinical candidate
  - Improved - dissolution kinetics and solubility
  - Improved PK and bioavailability
  - 2 patent applications filed




Proof-of-concept for re-engineering strategy

# AxP107-11: accentuate anti-tumor effect, inhibit metastasis and increase survival




Positioning; Anti-metastatic multi-targeted chemosensitizer

# Targeting of Cancer related Kinases by AXP107-11



Erlotinib  
317 Total kinases tested  
35 Kinases not mapped




AxP 107-11  
442 Total kinases tested  
78 Kinases not mapped

Novel multi-targeted kinase inhibition profile defined

# Combination Treatment

AXP107-11 and gemcitabine (EudraCT no: 2010-019214-25)



\*i.v. once a week

\*\* p.o. once a day

Improved overall survival, disease free interval and quality-of-life

# Financials & Business Model

- Series-A; completed Q3-2009 (amount undisclosed)
  - AXP107-11 phase Ib/IIa in patients with pancreatic cancer
  - Orphan drug application
  - Indication and formulation expansion of AXP107-11
  - Pre-clinical evaluation of additional compounds
  
- Business model
  - Pre marketing sales (“Compassionate use”)
  - Out-licensing of clinical proof of concept compounds

# Advisory Team



**Ronny Westberg, Clinical Key Opinion Leader**

Independent consultant, clinical trials in oncology



**Matthias Löhr, Clinical Key Opinion Leader Pancreatic Cancer**

Professor of Gastroenterology, M. D., Ph. D., Karolinska University Hospital



**Roger Henriksson, Clinical Key Opinion Leader Oncology**

Professor of Oncology, M. D., Ph. D. Head of Department Oncology, Karolinska University Hospital (September 1, 2009)



**Jeffrey A. Lindeman Key Opinion Leader Patenting of crystalline forms of pharmaceuticals**

Ph. D., Partner Nixon Peabody, Washington, Partner O'Brian Jones PLLC, Virginia, USA

Key opinion leaders endorse treatment concept  
and IP strategy